文献速递中枢神经肿瘤放疗头颈部肿瘤放疗

贝伐珠单抗单药治疗减少鼻咽癌患者放射性脑坏死:一项随机对照试验

Bevacizumab Monotherapy Reduces Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Patients: A Randomized Controlled Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-05-02

这项多中心开放标签随机试验将放射性脑坏死的鼻咽癌患者按1:1分为贝伐珠单抗组(5 mg/kg 静脉注射,每2周一次,共4周期)与糖皮质激素组,主要终点为2个月时基于MRI和临床症状的缓解率。贝伐珠单抗组缓解率为65.5%,显著高于糖皮质激素组的31.5%(P < .001),临床改善率亦更高(62.1% vs 42.6%,P = .039)。

要点

  • 贝伐珠单抗组2个月缓解率为65.5%,显著高于糖皮质激素组的31.5%(P < .001)。
  • 贝伐珠单抗组临床改善率为62.1%,糖皮质激素组为42.6%(P = .039)。
  • 贝伐珠单抗组最常见不良事件为高血压(20.6%)。

核心结论

  • 与糖皮质激素相比,贝伐珠单抗提供更好的症状缓解和影像学缓解。

研究设计与样本

  • 多中心开放标签随机对照试验,筛查121例,112例符合入组标准,按1:1随机分入贝伐珠单抗组或糖皮质激素组。

主要发现

  • 贝伐珠单抗组38例(65.5%)显示缓解,糖皮质激素组为31.5%(65.5% vs 31.5%,P < .001)。
  • 贝伐珠单抗组T1增强和T2-FLAIR MRI上放射性脑坏死体积平均下降百分比分别为25.5%和51.8%,糖皮质激素组分别为5.0%和19.3%。
  • 贝伐珠单抗组36例(62.1%)和糖皮质激素组23例(42.6%)显示临床改善(P = .039)。
  • 6个月随访期间,贝伐珠单抗组14例和糖皮质激素组13例出现放射性脑坏死复发。
  • 贝伐珠单抗组最常见不良事件为高血压(20.6%)。

关键数值与推荐

  • 贝伐珠单抗用法为5 mg/kg静脉注射,每2周一次,共4周期。
  • 糖皮质激素用法为甲泼尼龙500 mg/天静脉注射连续3天,随后逐渐减量,之后口服泼尼松10 mg/天,总共2个月。
  • 主要终点为2个月时基于MRI和临床症状确定的缓解率。
  • 所有患者随访6个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Studies have shown that addition of bevacizumab to corticosteroids improves outcome against radiation-induced brain necrosis (RN). Here, we aimed to evaluate the effectiveness and safety of bevacizumab monotherapy on RN in nasopharyngeal carcinoma (NPC) patients. METHODS AND MATERIALS: In this multicenter open-label study, patients with RN were randomly assigned (1:1) into a bevacizumab group (5 mg/kg intravenously every 2 weeks, for 4 cycles) or a corticosteroid group (methylprednisolone 500 mg/day intravenously for 3 consecutive days and then gradually tapered, followed by 10 mg/day oral prednisone, for 2 months in total). Magnetic resonance imaging (MRI) was performed pre- and post-treatment to define the radiographic response. The primary outcome was a 2-month response rate as determined by MRI and clinical symptoms. All of the patients were followed up with for 6 months. The trial was registered at www.clinicaltrials.gov (NCT01621880). RESULTS: Of 121 patients screened, 112 patients met the entry criteria. Thirty-eight (65.5%) patients in the bevacizumab group showed response, which was significantly higher than that in the corticosteroid group (65.5% vs 31.5%, P < .001). The mean percentage decrease in RN volume seen on T1 post-gadolinium and T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI was 25.5% and 51.8%, respectively, in the bevacizumab group, versus 5.0% and 19.3%, respectively, in the corticosteroid group. Moreover, 36 patients (62.1%) on bevacizumab and 23 patients (42.6%) on corticosteroids demonstrated clinical improvement (P = .039). During the 6-month follow up, fourteen patients on bevacizumab and 13 patients on corticosteroids showed RN recurrence. The most frequent adverse event in the bevacizumab group was hypertension (20.6%). CONCLUSIONS: Our study indicate that compared with corticosteroids, bevacizumab offers improved symptomatic relief and radiographic response.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Xu Y, Rong X, Hu W, et al. Bevacizumab Monotherapy Reduces Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Patients: A Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 29885994. doi:10.1016/j.ijrobp.2018.04.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。